{"certainAgreement":{"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase."},"pointOfContact":{"email":"Clinical.Trials@bms.com","organization":"Bristol-Myers Squibb","title":"BMS Study Director"}}